Can MRI of the Prostate Combined With a Radiomics Evaluation Determine the Invasive Capacity of a Tumour (MRI-PREDICT)
Prostate Cancer
About this trial
This is an interventional diagnostic trial for Prostate Cancer focused on measuring Magnetic Resonance Imaging, Radiomics, Non-invasive, Cancer Diagnosis, Staging, Prostate Cancer
Eligibility Criteria
Inclusion Criteria:
An appropriate diagnostic MRI-P, defined as:
- Being performed on 3T MRI at the Halifax Infirmary Building
- Taken place within 5 weeks of study enrolment
- Having a detectable nodule which anatomically localizes to prostate cancer (PCa) identified in diagnostic biopsy specimen
- Acquired T1+contrast, T2, and attenuated diffusion coefficient (ADC) series axial images of the prostate
An appropriate diagnostic biopsy, defined as:
- Taken place within 2 months of the participant's MRI-P 1
- Taken place within 3 months of participant's study enrolment
- Reports diagnosis of PCa
- Reports a systematic assessment of the biopsy, assessing at least 12 cores
- Reports at least on core involved with PCa and this core must anatomically localise to a nodule seen on MRI-P 1
Exclusion Criteria:
- Past prostatic interventions which would influence the prostate's structure
- Alterations to physiological testosterone levels
- Inability to position one's self in a reproducible fashion for an MRI-P
- Patient factors reported to produce significant artifact on MRI-P 1
Sites / Locations
- Victoria General HospitalRecruiting
Arms of the Study
Arm 1
Experimental
Prospective Cohort
Sixty patients with a new diagnosis of prostate cancer that meet eligibility criteria. The group will have two standard MRI-P's completed. The first MRI-P will be acquired as standard of care and the second will be an additional investigation for the purposes of this study. The efficacy of the MRT will be compared at both time points, evaluating if the MRT demonstrates clinically sufficient stability in its findings (i.e., does the MRT report an accurate and similar result at both time points).